直击业绩会|药明合联2024年归母净利润“狂飙”277% 维持今年35%收入增幅预测不变

每日经济新闻
25 Mar

每经记者 陈星 每经编辑 杨夏3月24日晚,药明合联(02268.HK,股价39.95港元,市值480亿港元)发布2024年业绩公告,实现全年营业收入40.52亿元人民币,同比增长90.8%;毛利润达12.40亿元人民币,增速高达121.6%;归母净利润更同比大增277%至10.70亿元。值得一提的是,近年来中国药企的ADC药物(抗体偶联药物)项目“出海”势头凶猛,这也带动了药明合联的业绩。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10